Uthaya Kumaran Kanagaraj

Dr. Uthaya Kumaran Kanagaraj

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
UKUthaya Kumaran Kanagaraj
Uthaya Kumaran Kanagaraj
TKTapas Kulkarni
Tapas Kulkarni
EKEddie Kwan
Eddie Kwan
QZQian Zhang
Qian Zhang
JBJeffery Bone
Jeffery Bone
SSSandesh Shivananda
Sandesh Shivananda
Background/Objectives: The numerical risk of bronchopulmonary dysplasia (BPD) and/or death could be estimated using the National Institute of Child Health and Human Development (NICHD) BPD outcome estimator 2022 in extremely low gestational age (ELGA) infants during the first 4 weeks of life to facilitate prognostication, and center-specific targeted improvement interventions. However, the 2022 NICHD BPD outcome estimator’s performance in the Canadian setting has not been validated. Our objective is to validate the NICHD BPD outcome estimator 2022 in predicting death and or moderate to severe BPD at 36 weeks in infants less than 29 weeks admitted to NICU. Methods: A retrospective observational study (March 2022–August 2023) was conducted on both inborn and outborn preterm infants excluding neonates with major congenital anomalies. Infants were classified into six groups based on the predicted risk of death or Grade 2 or 3 BPD ( 0.7 defined a priori as an acceptable predictive accuracy for local use. Results: Among 99 infants included, 13 (13.1%) died, and 40 (40.4%) developed BPD. Median gestational age was 26 weeks, and median birth weight was 914 g. Twenty-three infants (23.2%) received postnatal steroids. The AUC values for death or moderate to severe BPD on days 1, 3, 7, 14, and 28 were 0.803, 0.806, 0.837, 0.832, and 0.843, respectively. The AUC values for moderate to severe BPD alone on those days were 0.766, 0.746, 0.785, 0.807, and 0.818 respectively. Conclusions: The 2022 BPD estimator adequately predicted the death and/or moderate to severe BPD on days 1, 3, 7, 14, and 28 of life. This tool could serve as a valid adjunct to facilitate discussion between clinicians and families on initiating time-sensitive targeted interventions to prevent or alter the course of BPD.

24 February 2021 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
PDF file
UKUthaya Kumaran Kanagaraj
Uthaya Kumaran Kanagaraj
SGSeema Gaonkar
Seema Gaonkar
MCMaitri Chaudhuri
Maitri Chaudhuri
ASAjmeer K Sheriff
Ajmeer K Sheriff
NRNilesh Rao
Nilesh Rao
ASArvind Shenoi
Arvind Shenoi

17 April 2022 in Journal of Neonatology
Verified
Journal Article
Closed access
UKUthaya Kumaran Kanagaraj
Uthaya Kumaran Kanagaraj
ASArvind Shenoi
Arvind Shenoi
Persistent pulmonary hypertension of newborn is being increasingly diagnosed in extremely premature infants, especially if associated with preterm prelabour rupture of membranes and lung hypoplasia. Late-onset pulmonary hypertension (PH) associated with bronchopulmonary dysplasia is because of pulmonary vascular remodeling and altered vasoreactivity. PH in both these settings is associated with around 20% increase in higher mortality and morbidity. The steps in the management of early-onset PH in these neonates, like in term infants, are supportive measures, oxygenation, lung recruitment, and ventilation. In extremely preterm infants, PH occurs because of the paucity of the pulmonary vascular bed and may not respond well to pulmonary vasodilators, such as iNO and sildenafil. Magnesium sulfate can be effective in reducing the pulmonary pressure, especially in resource-limited settings. Milrinone is considered in neonates with PH and poor cardiac function. In preterm infants with PH secondary to bronchopulmonary dysplasia, the emphasis is on oxygen therapy, nutrition, and correction of comorbidities along with some role of vasodilators.

30 March 2021 in Journal of Neonatology
Verified
Journal Article
Closed access
PDF file
UKUthaya Kumaran Kanagaraj
Uthaya Kumaran Kanagaraj
ASArvind Shenoi
Arvind Shenoi
Pulmonary hypertension (PH) in the term newborn is associated with roughly one-fifth higher mortality and morbidity. The diagnosis of PH is confirmed by echocardiogram based on established criteria, including assessment of cardiac function, size of the shunts, and presence of hypovolemia. The elementary steps in the management of PH are supportive measures followed by oxygenation, ventilation including possibly high frequency ventilation; lung recruitment and surfactant therapy. Ventilation strategies are based on the etiology of persistent pulmonary hypertension of the newborn (PPHN)-like lung parenchymal disease, or hypoplasia. Oxygenation index (OI) or oxygen saturation index (OSI) are the parameters used for monitoring the disease progression and treatment. Surfactant is given if OI >5 in PPHN due to underlying lung disease, and pulmonary vasodilators such as sildenafil are contemplated if OI 15. If iNO and sildenafil fail, the options available are milrinone, bosentan, adenosine, and prostaglandins. Extra corporeal membrane oxygenation is the final option available with OI >40. A structured algorithmic approach for the management of PH in term infants is discussed in this review. Novel therapies targeting specific pathways in the pulmonary vasculature are under investigation.

Verified
Journal Article
Open access
PDF file
ASAvram R. Shack
Avram R. Shack
TKTapas Kulkarni
Tapas Kulkarni
AHAlyssa Hawley
Alyssa Hawley
JJJessy Jagpal
Jessy Jagpal
MJManinder Janda
Maninder Janda
SSSandesh Shivananda
Sandesh Shivananda
Background/Objectives: Bronchopulmonary dysplasia (BPD) remains a major morbidity among extremely premature infants, with variability in the application of evidence-based interventions between and within neonatal intensive care units (NICUs). We evaluated a multi-component, risk-guided personalized implementation strategy for BPD prevention in a real-world setting. Methods: We conducted a prospective observational study of infants <29 weeks’ gestation at birth admitted to a quaternary NICU. The intervention combined risk stratification and structured longitudinal care planning rounds (LCPRs) that included standardized documentation, multidisciplinary facilitation, and associated continuous quality improvement strategies. Implementation outcomes were assessed using the reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) framework. Secondary outcomes included care processes, provider-reported measures, and exploratory clinical outcomes. Results: Over six months, 41 infants were included. Risk stratification was consistently applied and all fifteen high-risk infants received LCPR, demonstrating targeted reach. Multidisciplinary participation was broad, with implementation fidelity reflected by consistent screening, structured documentation, and timely care plan execution. Practice standardization was observed, including consistent corticosteroid use (100%), earlier initiation of systemic postnatal steroids (median 16 days), and selective adjunctive therapy use. Providers reported improved teamwork, care coordination, and confidence. Rates of BPD or mortality were comparable between higher-risk infants receiving LCPR and lower-risk infants, despite greater illness severity in the LCPR group. Respiratory severity scores showed a downward trend after implementation, though this did not reach statistical significance (p = 0.07). Strategy use continued beyond the study period indicating early sustainability. Conclusions: A multi-component, risk-guided implementation strategy can be effectively integrated into routine NICU practice, improving care processes while maintaining clinical outcomes in high-risk infants compared with lower-risk infants.

13 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
UKUthaya Kumaran Kanagaraj
Uthaya Kumaran Kanagaraj
TKTapas Kulkarni
Tapas Kulkarni
EKEddie Kwan
Eddie Kwan
JBJeffery Bone
Jeffery Bone
SSSandesh Shivananda
Sandesh Shivananda
Background/Objectives: The numerical risk of bronchopulmonary dysplasia (BPD) and/or death could be estimated using the National Institute of Child Health and Human Development (NICHD) BPD outcome estimator 2022 in extremely low gestational age (ELGA) infants during the first 4 weeks of life to facilitate prognostication, and centre specific targeted improvement interventions. However, 2022 NICHD BPD outcome estimator’s performance in Canadian setting has not been validated. Our objective is to validate the NICHD BPD outcome estimator 2022 in predicting death and or moderate to severe BPD at 36 weeks in less than 29 weeks infants admitted to NICU. Methods: A retrospective observational study (March 2022–August 2023) was conducted on both inborn and outborn preterm infants excluding neonates with major congenital anomalies. Infants were classified into five groups based on the predicted risk of death or moderate-to-severe BPD (0.7 defined a priori as an acceptable predictive accuracy for local use. Results: Among 99 infants included, 13 (13.1%) died, and 40 (40.4%) developed BPD. Median gestational age was 26 weeks, and median birth weight was 914 grams. Twenty-three infants (23.2%) received postnatal steroids. The AUC values for death or moderate to severe BPD on days 1, 3, 7, 14, and 28 were 0.803, 0.806, 0.837, 0.832, and 0.843, respectively. The AUC values for moderate to severe BPD alone on those days were 0.766, 0.746, 0.785, 0.807 and 0.818 respectively. Conclusions: The 2022 BPD estimator accurately predicted the death and /or moderate to severe BPD on Days 1, 3, 7, 14 and 28 of life. This tool could serve as a valid adjunct to facilitate discussion between clinicians and families on initiating time-sensitive targeted interventions to prevent or alter the course of BPD.